IL1RAP and acute myeloid leukemia: Although we demonstrate that IL1RAP is preferentially expressed by NKt-AML, our results indicate that other AML subgroups such as t(6;9) and t(8;21) AML express relatively high levels of IL1RAP and might benefit from immunotherapeutic strategies targeting IL1RAP.